The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2020 | CAR T-cell therapy horizon scan
Michel Delforge, MD, PhD, University of Leuven, Leuven, Belgium, discusses the future of chimeric antigen receptor (CAR) T-cell therapy in multiple myeloma and outlines his highlights from ASH 2020. In the longer term, Dr Delforge believes that CAR T-cell therapy will be used in earlier settings and in higher-risk subgroups of multiple myeloma patients. In the shorter-term, he highlights research aiming to achieve longer persistence of CAR T-cells, the development of new manufacturing technologies, and the possibility of dual-targeting and allogeneic CAR T-cell therapies. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
Disclosures
Michel Delforge, MD, PhD, has participated in advisory boards for Amgen, Celgene-BMS, GSK, Janssen, Takeda and Sanofi; and has received research grants from Amgen, Celgene, Janssen, Takeda and Sanofi.
